Testing version — LOERadar is in active testing. Features and data may change.
GALLIUM GA 68 GOZETOTIDE (GALLIUM GA-68 GOZETOTIDE) | LOERadar
GALLIUM GA 68 GOZETOTIDE
NDA
GALLIUM GA-68 GOZETOTIDE | N212643 | UNIV OF CALIFORNIA SAN FRANCISCO
1 strength0 unique patents0 unique exclusivities
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — 0.5-5mCi/mL
RLDAP
0 patents0 exclusivities▴
SOLUTION;INTRAVENOUS | Approved: Dec 1, 2020
No patent or exclusivity listings for this strength.
Change History (1)
Recent changes detected for this application.
MODIFIEDTE Code7/1/2026
University of California San Francisco's Gallium Ga-68 Gozetotide (NDA 212643) received an AP therapeutic equivalence rating, designating it as therapeutically equivalent to reference products.